Studies demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) could reverse steatohepatitis, reduce cardiovascular risk, and improve NASH histology without worsening fibrosis in middle-aged patients (50). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.